Using single-cell RNA and T cell receptor sequencing along with microscopy, we identified the cell types and genes associated with immune checkpoint inhibitor therapy-related colitis. Our study will help to identify targets for early diagnosis and lays the groundwork for the development of safer immunotherapy regimens.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018). A review article that presents an overview of common and distinct features of IRAEs across organ systems.
Bai, X. et al. Early use of high-dose glucocorticoid for the management of irae is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. Clin. Cancer Res. 27, 5993–6000 (2021). This paper reports that patients with melanoma who receive high-dose steroids to treat IRAEs have worse overall survival.
Blum, S. M. et al. Immune responses in checkpoint myocarditis across heart, blood, and tumor. Preprint at bioRxiv https://doi.org/10.1101/2023.09.15.557794 (2023). A preprint manuscript from our research group on the biological underpinnings of checkpoint inhibitor-associated myocarditis.
Boland, B. S. et al. Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Sci. Immunol. 5, eabb4432 (2020). A study assessing clonal sharing among patients with ulcerative colitis finds T cell receptor sharing between intestinal and blood CD8+ T cell populations, similar to those described in our study.
Zubiri, L. et al. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J. Immunother. Cancer 9, e002886 (2021). This paper presents an overview of the Massachusetts General Hospital Severe Immunotherapy Service and its effect on patient outcomes.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Fisher Thomas, M. et al. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis. Nat. Med. https://doi.org/10.1038/s41591-024-02895-x (2024).
Rights and permissions
About this article
Cite this article
Studying paired patient tissue and blood enables insights into immunotherapy toxicity. Nat Med (2024). https://doi.org/10.1038/s41591-024-02900-3
Published:
DOI: https://doi.org/10.1038/s41591-024-02900-3
